Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA says
Send a link to a friend
 [April 18, 2024]
(Reuters) -Most doses of Eli Lilly's diabetes drug Mounjaro and
weight-loss drug Zepbound would be in limited supply through the second
quarter of this year due to increased demand, the U.S. Food and Drug
Administration's website showed on Wednesday.
Both drugs had limited availability for the 5 milligram (mg), 7.5 mg, 10
mg, 12.5 mg and 15 mg doses, the website noted. The 2.5 milligram doses
for the treatments were listed as available.
Previously, some doses of both the drugs were expected to be available
in limited quantities through April. Doses of Mounjaro have been
available in limited amounts since February.
The 1.5 mg and 4.5 mg doses of Trulicity, another diabetes drug by
Lilly, will also be available in limited amounts through April due to
increased demand, according to the FDA's website.
Increasing demand for a type of highly effective diabetes and
weight-loss treatment known as GLP-1 agonists has led to supply
constraints for drugmakers such as Lilly and Novo Nordisk.
"While we anticipate limited availability in the near term, we expect
our investments in manufacturing and supply capacity to progressively
increase production of our medicines throughout 2024 and beyond," a
spokesperson for Lilly said.
[to top of second column]
|
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is
displayed in New York City, U.S., December 11, 2023. REUTERS/Brendan
McDermid
 The drugmaker has also advised
patients to plan ahead for refills of their medicines by contacting
their pharmacy at least one week before the refill is needed.
Mounjaro has been approved since 2022 for patients with type-2
diabetes to control their blood sugar levels. It was approved in the
U.S. for weight loss under the brand name Zepbound late last year.
Separately, Lilly said earlier on Wednesday that tirzepatide - the
active ingredient in both Mounjaro and Zepbound - helped ease
symptoms of a common sleep-related breathing disorder across two
late-stage studies.
(Reporting by Bhanvi Satija, Sneha S K and Sriparna Roy in Bengaluru;
Editing by Devika Syamnath and Shailesh Kuber)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
